AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer

被引：7
|
作者：
Spirina, L. V. [1 ,2 ]
Avgustinovich, A. V. [1 ]
Afanas'ev, S. G. [1 ]
Kondakova, I. V. [1 ]
Volkov, M. Yu. [1 ]
Dobrodeev, A. Yu. [1 ]
Boronkina, A. I. [2 ]
机构：
[1] Tomsk Natl Res Med Ctr, Canc Res Inst, Tomsk, Russia
[2] Siberian State Med Univ, Minist Hlth Russian Federat, Tomsk, Russia
来源：
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE | 2020年 / 170卷 / 01期
关键词：
gastric cancer; AKT; mTOR signaling cascade; PD; PD-L1; PD-L2; PATHWAY; AKT;
D O I：
10.1007/s10517-020-05007-0
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The peculiarities of gastric cancer development associated with the expression levels of components of the AKT/mTOR signaling cascade and PD, PD-L1, PD-L2 have not yet been identified. We revealed the fundamental changes in the expression AKT/mTOR and PD receptors and their ligands associated with dissemination of gastric cancer. An increase in the mRNA level of all components of this cascade was demonstrated. The expression of mTOR and AKT decreased against the background of enhanced expression of PTEN phosphatase. The increase in the expression of PD-1 receptors and PD-L1 and PD-L2 ligands was most pronounced in patients with distant metastases.
引用
收藏
页码：75 / 78
页数：4
相关论文
共 50 条
  • [41] PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome
    Obeid, Joseph M.
    Erdag, Gulsun
    Smolkin, Mark E.
    Deacon, Donna H.
    Patterson, James W.
    Chen, Leiping
    Bullock, Timothy N.
    Slingluff, Craig L.
    ONCOIMMUNOLOGY, 2016, 5 (11):
  • [42] PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
    Larsen, Trine Vilsboll
    Hussmann, Dianna
    Niesen, Anders Lade
    CANCER COMMUNICATIONS, 2019, 39
  • [43] PD-1/PD-L1 antagonists in gastric cancer:Current studies and perspectives
    Jian Li
    Xiao-Hong Zhang
    Song-Hua Bei
    Li Feng
    World Journal of Meta-Analysis, 2019, (03) : 101 - 109
  • [44] High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood
    Krueger, Kimberly
    Mayer, Zsuzsanna
    Gerckens, Miriam
    Boeck, Stefan
    Luppa, Peter
    Holdenrieder, Stefan
    BIOMEDICINES, 2022, 10 (10)
  • [45] Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer
    Ito, Shuhei
    Masuda, Takaaki
    Noda, Miwa
    Hu, Qingjiang
    Shimizu, Dai
    Kuroda, Yosuke
    Eguchi, Hidetoshi
    Tobo, Taro
    Utsunomiya, Tohru
    Mimori, Koshi
    ONCOLOGY, 2020, 98 (07) : 501 - 511
  • [46] PD-L1/PD-1 blockade in breast cancer: The immunotherapy era
    Li, Chia-Jung
    Lin, Li-Te
    Hou, Ming-Feng
    Chu, Pei-Yi
    ONCOLOGY REPORTS, 2021, 45 (01) : 5 - 12
  • [47] Role of regulation of PD-1 and PD-L1 expression in sepsis
    Teng, Zhang
    Li, Yu-Jing
    Tao, Ma
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [48] Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy
    Yu, Xianzhe
    Zhai, Xiaoqian
    Wu, Juan
    Feng, Qingbo
    Hu, Chenggong
    Zhu, Lingling
    Zhou, Qinghua
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2024, 1870 (01):
  • [49] Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer
    Yun, Tian
    Wang, Sunan
    Jiang, Bo
    Wang, Changsong
    Meng, Nianlong
    Yuan, Xutao
    Wang, Yangkun
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [50] Identification of the exosomal PD-L1 inhibitor to promote the PD-1 targeting therapy of gastric cancer
    Sun, Jian-Gang
    Gao, Ya
    Gao, Yong-Shun
    Dai, Xing-Jie
    Chen, Peng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 268
12345